Zomedica Corp
AMEX:ZOM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.118
0.178
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Zomedica Corp
Net Income (Common)
Zomedica Corp
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Z
|
Zomedica Corp
AMEX:ZOM
|
Net Income (Common)
-$62.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-92%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Net Income (Common)
$1.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Net Income (Common)
$1.8B
|
CAGR 3-Years
18%
|
CAGR 5-Years
10%
|
CAGR 10-Years
20%
|
|
|
Stryker Corp
NYSE:SYK
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
19%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Net Income (Common)
$5.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Net Income (Common)
$2.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
18%
|
|
Zomedica Corp
Glance View
Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 85 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's Diagnostics segment consists of TRUFORMA products. Its Therapeutics segment consists of PulseVet and Assisi products. Its TRUFORMA Bulk Acoustic Wave (BAW) point-of-care diagnostic platform is marketed with full diagnostic and thyroid panels for dogs and cats that include the only assays of these types available at the point of care to test for feline optimized TSH, endogenous ACTH, Free T4, and quantitative cortisol, along with a total T4 assay. The VetGuardian is its zero-touch vital signs remote monitoring system that enables contact-free, continuous monitoring of a pet's vital signs. The PulseVet is its electrohydraulic shockwave therapy platform. Its Assisi Loop line of products treats pain and inflammation through the delivery of targeted pulsed electromagnetic field focused energy (tPEMF).
See Also
What is Zomedica Corp's Net Income (Common)?
Net Income (Common)
-62.2m
USD
Based on the financial report for Sep 30, 2024, Zomedica Corp's Net Income (Common) amounts to -62.2m USD.
What is Zomedica Corp's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-92%
Over the last year, the Net Income (Common) growth was -316%. The average annual Net Income (Common) growth rates for Zomedica Corp have been -48% over the past three years , -20% over the past five years , and -92% over the past ten years .
You don't have any saved screeners yet